Differentiating meropenem and imipenem/cilastatin

Infectious Diseases in Clinical Practice

Volumn 6, Issue 5, 1997, Pages 291-303

  Norrby, S Ragnar ^a,c   Faulkner, Karen L ^b   Newell, Paul A ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFOTAXIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; MEROPENEM; METRONIDAZOLE; NETILMICIN; PIPERACILLIN; TAZOBACTAM; TOBRAMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MIXTURE; GASTROINTESTINAL SYMPTOM; HOSPITAL PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRACTICE GUIDELINE; RESPIRATORY TRACT INFECTION; SEIZURE; SHORT SURVEY; VOMITING;

EID: 0030753271     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199706050-00003     Document Type: Short Survey

References (75)

1. Kahan FM, Kropp H, Sundelof JG, et al. Thienamycin: development of imipenem-cilastatin. J Antimicrob Chemother 1983;12 Suppl D:1-35.
2. Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect, and against staphylococci. J Antimicrob Chemother 1989;24 Suppl A:125-32.
3. Sumita Y, Fukasawa M, Okuda T. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and its release from these proteins and morphological changes. J Antibiot 1990;43:314-20.
4. Zeneca Pharmaceuticals, data on file.
5. Edwards JR, Turner PJ. Laboratory data which differentiate meropenem from imipenem. Scand J Infect Dis 1995; Suppl 96:5-10.
6. Fuchs PC, Barry AL, Brown SD. Pneumococcal susceptibility to meropenem. J Antimicrob Chemother 1996;37: 1036-7.
7. Livermore DM. Bacterial resistance to carbapenems. Adv Exp Med Biol 1995;390:25-47.
8. Mouton Y, Debosker Y, Bazin C, et al. Prospective, randomised controlled trial of imipenem/cilastatin vs. cefotaxime-amikacin in the treatment of lower respiratory tract infections and septicaemia in intensive care units. Presse Med 1990;19:607-12.
9. Sanders CC, Sanders WE. Beta-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992;15:824-39.
10. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36 Suppl A:1-17.
11. Birnbaum J, Kahan FM, Kropp H, MacDonald S. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985;78 Suppl A:3-21.
12. Norrby SR, Björnegård B, Ferber F. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 1983;12 Suppl D:109-24.
13. Sunagawa M, Matsumura HM, Inoue T, Fukasawa M, Kato M. A novel carbapenem antibiotic, SM-7338 structure-activity relationships. J Antibiot 1990;43:519-32.
14. Topham JC, Murgatroyd LB, Jones DV, Goonetilleke URP, Wright J. Safety evaluation of meropenem in animals. Studies on the kidney. J Antimicrob Chemother 1989;24 Suppl A:287-306.
15. Parker EM, Hutchison M, Blumer JL. The pharmacokinetics of meropenem in infants and children: a population analysis. J Antimicrob Chemother 1995;36 Suppl A:63-71.
16. Winston DJ, Winston G, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 1991;115:849-59.
17. Physicians' desk reference. Montvale (NJ): Medical Economics Company, 1996.
18. Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother 1995;36 Suppl A:43-56.
19. Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989;24 Suppl A:311-20.
20. Drusano GL. An overview of the pharmacology of imipenem/cilastatin. J Antimicrob Chemother 1986;18 Suppl E:79-92.
21. Keller E, Fecht H, Böhler J, Schollmeyer P. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Nephrol Dial Transplant 1989;4:640-5.
22. Norrby SR, Rogers JD, Ferber F, et al. Disposition of radio-labeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother 1984;26:707-14.
23. Christensson BA, Nilsson-Ehle I, Hutchison M. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. J Antimicrob Chemother 1992;36:1532-7.
24. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988;84:911-8.
25. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996;51:99-136.
26. Hamacher J, Vogel J, Lichey J, et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients-a comparison of meropenem and imipenem-cilastatin. J Antimicrob Chemother 1995;36 Suppl A:121-33.
27. Geroulanos SJ, and the Meropenem Study Group. Meropenem vs. imipenem/cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother 1995;36 Suppl A:191-205.
28. Colardyn F, Faulkner KL, on behalf of the Meropenem Serious Infection Study Group. Intravenous meropenem vs. imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996;38:523-37.
29. Mouton YJ, Beuscart C, and the Meropenem Study Group. Empiric monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995;36 Suppl A:145-56.
30. Condon RE, Walker PA, Sirinek KR, et al. Meropenem vs. tobramycin plus clindamycin for treatment of intra-abdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995;21:544-50.
31. Berne TV, Appleman MD, Heseltine PNR, Yellin AE, Gill MA. Meropenem vs. tobramycin with clindamycin in the antibiotic management of advanced appendicitis. J Am Coll Surg 1996;182:403-7.
32. Huizinga WKJ, Warren BL, Baker P, et al Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995;36 Suppl A:179-89.
33. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam vs. imipenem/cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-73.
34. Solomkin JS, Dellinger EP, Christou NV, et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990;212:581-91.
35. Cometta A, Baumgarter JD, Lew D, et al. Prospective randomised comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38:1309-13.
36. Norrby SR, Finch RG, Glauser M, and the European Study Group. Ceftazidime vs. imipenem/cilastatin as monotherapy of serious hospital acquired infections. J Antimicrob Chemother 1993;31:927-37.
37. Solomkin JS, Rheinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/ oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg 1996;223:303-15.
38. Fink MP, Snydman D, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin Antimicrob Agents Chemother 1994;38:547-57.
39. Mandell LA, Turgeon PL, Ronalds AR, Canadian Trials Group. A prospective randomized trial of imipenem-cilastatin vs. clindamycin/tobramycin in the treatment of intra-abdominal and pelvic infections. Can J Infect Dis 1993;4:279-87.
40. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics Antimicrob Agents Chemother 1992;36:2577-83.
41. Nilsson-Ehle I, Hutchison M, Haworth SJ, et al. Pharmacokinetics of meropenem compared to imipenem/cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 1991;10:85-8.
42. Walker R, Andes D, Conkin R, et al. Pharmacodynamic activities of meropenem in an animal infection model [abstract A91]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; Orlando (FL). Washington (DC): American Society for Microbiology, 1992:147.
43. Drusano GL. The pharmacokinetics of meropenem. Scand J Infect Dis 1995; Suppl 96:11-6.
44. Romanelli G, Cravarezza P, and the Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and respiratory tracts J Antimicrob Chemother. 1995;36 Suppl A:109-19.
45. Cox CE, Holloway WJ, Geckler RW. A multicenter comparison of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995;21:86-92.
46. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem vs. imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995;88:397-404.
47. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem vs. imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995;35:139-48.
48. Stille W, and the German and Austrian Imipenem/Cilastatin Study Group. Randomised multicentre clinical trial with imipenem/cilastatin vs. cefotaxime/gentamicin in the treatment of patients with non-life threatening infections. Eur J Clin Microbiol Infect Dis 1992;11:683-92.
49. Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem vs. ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother 1995;36 Suppl A:135-43.
50. Schuler D, and the Meropenem Paediatric Study Group. Safely and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. J Antimicrob Chemother 1995;36 (Suppl A):99-108.
51. Schmutzhard E, Williams KJ, Vukmirovits G, et al , and the Meropenem Meningitis Study Group. A randomized comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother 1995;36 Suppl A:85-98.
52. Klugman KP, Dagan R, and the Meropenem Meningitis Study Group. Randomized comparison of meropenem and cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 1995;39:1140-6.
53. Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem vs. piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992;30:843-54.
54. Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
55. Deaney NB, Tate H. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. J Antimicrob Chemother 1996;37:975-86.
56. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem vs. combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
57. Immunocompromised Host Society Consensus Panel. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990;161:397-401.
58. Gudmundsson S, Einarsson S, Erlendsdottir H, et al. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model J Antimicrob Chemother 1993;31 Suppl D:177-91.
59. Meropenem Study Group of London, Leuven, and Nijmegen. Equivalent efficacy of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995;36:185-200.
60. Dagan R, Velghe L, Rodda JL, Klugman KP. Penetration of meropenem into cerebrospinal fluid in humans with inflamed meninges. J Antimicrob Chemother 1994;34:175-9.
61. Patel JB, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989;24 Suppl A:307-9.
62. De Sarro A, Ammendola D, Zappala M, et al. Relationship between structure and convulsant properties of some β-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995; 39:232-7.
63. Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10:122-5.
64. Bradley JS, Faulkner KL, Klugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J 1996; 15:749-57.
65. Nalin DR, Jacobsen CA. Imipenem/cilastatin therapy for serious infections in neonates and infants. Scand J Infect Dis 1987; Suppl 52:46-55.
66. Martinkova J, de Groot de R, Chladek J, et al. Meropenem pharmacokinetics in pre-term and full term neonates [abstract 686]. Poster presented at the 7th European Congress of Clinical Microbiology and Infectious Diseases; Vienna, Austria: 1995:133.
67. Stuart RL, Turnridge J, Grayson ML. Safety of imipenem in neonates. Pediatr Infect Dis J 1995;14:804-5.
68. Scharf J, Krüger C, Guggenbichler JP. Therapy of preterm and term neonates with imipenem/cilastatin -tolerability and safety. Padiatr Grenzgeb 1994;32:461-9.
69. Hori S, Kanemitsu K, Shimida J. Epileptogenic activity of meropenem. A new carbapenem. A comparative study on epileptogenic activity of carbapenems and beta-lactams [abstract 301]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Anaheim (CA). Washington (DC): American Society for Microbiology, 1992:161.
70. Sunagawa M, Matsumura H, Fukasawa M. Structure-activity relationships of carbapenem and penem compounds for the convulsive property. J Antibiot 1992;45:1983-5.
71. Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995;36 Suppl A:207-23.
72. Norrby SR, Vandercam B, Louie T. Imipenem/cilastatin vs. amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multiclinic study. Scand J Infect Dis 1987; Suppl 52:65-78.
73. Wang C, Calandra GB, Aziz MA, Brown KR. Efficacy and safety of imipenem/cilastatin: a review of world-wide clinical experience. Rev Infect Dis 1985;7 (3 Suppl):528S-536S.
74. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime vs. imipenem J Clin Oncol. 1995;13:165-76.
75. Norwegian Study Group. Imipenem/cilastatin as monotherapy in severe infections: comparison with cefotaxime in combination with metronidazole and cloxacillin. Scand J Infect Dis 1987;19:667-75.